Effects of first high-dose atorvastatin loading in patients with st-segment elevation myocardial infarction undergoing percutaneous coronary intervention

American Journal of Therapeutics

Volumn 25, Issue 3, 2016, Pages E291-E298

  Li, Qiang ^a   Zhao, Yong Gang ^b   Wang, Zhen ^a   Jiang, Hai Peng ^a   Liu, Wen Bo ^a   Cao, Bing Feng ^c  

^a YANTAISHAN HOSPITAL   (China)

^b Department of Surgical Medicine First Hospital of Zibo City   (China)

^c Wendeng Central Hospital of Weihai   (China)

Author keywords

Atorvastatin; HbA1c; MACE; No reflow; Percutaneous coronary intervention; STEMI

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; HEMOGLOBIN A1C; TIROFIBAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL RATE; THERAPY EFFECT; BLOOD; DIAGNOSTIC IMAGING; DOSE RESPONSE; EMERGENCY TREATMENT; MIDDLE AGED; NO REFLOW PHENOMENON; PERIOPERATIVE PERIOD; PREOPERATIVE CARE; PROCEDURES; TREATMENT OUTCOME;

AGED; ATORVASTATIN; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; EMERGENCY TREATMENT; FEMALE; GLYCATED HEMOGLOBIN A; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PERIOPERATIVE PERIOD; PREOPERATIVE CARE; ST ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 84959105269     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000370     Document Type: Article

References (18)

1. Deshpande A, Birnbaum Y. ST-segment elevation: Distinguishing ST elevation myocardial infarction from ST elevation secondary to nonischemic etiologies. World J Cardiol. 2014;6:1067-1079.
2. Kurtul A, Ocek AH, Murat SN, et al. Serum albumin levels on admission are associated with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Angiology. 2015;66:278-285.
3. Liu Y, Su Q, Li L. Efficacy of short-term high-dose atorvastatin pretreatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of nine randomized controlled trials. Clin Cardiol. 2013;36:E41-E48.
4. Zhou SS, Tian F, Chen YD, et al. Combination therapy reduces the incidence of no-reflow after primary percutaneous coronary intervention in patients with STsegment elevation acute myocardial infarction. J Geriatr Cardiol. 2015;12:135-142.
5. Zhao XJ, Liu XL, He GX, et al. Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion. Braz J Med Biol Res. 2014;47:245-251.
6. Reiner Z. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10:453-464.
7. Haring R, Baumeister SE, Lieb W, et al. Glycated hemoglobin as a marker of subclinical atherosclerosis and cardiac remodeling among non-diabetic adults from the general population. Diabetes Res Clin Pract. 2014;105: 416-423.
8. Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383-2389.
9. Fu XH, Fan WZ, Gu XS, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction. Chin Med J (Engl). 2007;120:1226-1231.
10. Hong YJ, Jeong MH, Choi YH, et al. Impact of plaque components on no-reflow phenomenon after stent deployment in patients with acute coronary syndrome: A virtual histology-intravascular ultrasound analysis. Eur Heart J. 2011;32:2059-2066.
11. Gershlick AH, de Belder M, Chambers J, et al. Role of non-invasive imaging in the management of coronary artery disease: An assessment of likely change over the next 10 years. A report from the British Cardiovascular Society Working Group. Heart. 2007;93:423-431.
12. van der Loo B, Spring S, Koppensteiner R. High-dose atorvastatin treatment in patients with peripheral arterial disease: Effects on platelet aggregation, blood rheology and plasma homocysteine. Clin Hemorheol Microcirc. 2011;47:241-251.
13. Gong X, Ma Y, Ruan Y, et al. Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta. Exp Gerontol. 2014;52:9-17.
14. Ludka FK, Zomkowski AD, Cunha MP, et al. Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels. Eur Neuropsychopharmacol. 2013;23:400-412.
15. Momi S, Monopoli A, Alberti PF, et al. Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis. Cardiovasc Res. 2012;94: 428-438.
16. Foster T, Budoff MJ, Saab S, et al. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011;106:71-77.
17. Zhang Y, Hu G, Yuan Z, et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: A systematic review and meta-analysis. PLoS One. 2012;7:e42551.
18. Kalousova M, Zima T, Tesar V, et al. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif. 2002; 20:531-536.